J&J Advances Wet AMD and DME Strategy With Ollin Acquisition

Share on Social Media

Johnson & Johnson's acquisition of Ollin Biosciences to advance its retinal disease pipeline with OLN324.
Image: Pixels

Johnson & Johnson will acquire Ollin Biosciences for $2.2 billion, adding Phase 3 bispecific antibody OLN324 for wet AMD and diabetic macular edema.

Written By: Mayuri Vaja, PharmD

Reviewed By: Pharmacally Editorial Team

Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront, adding OLN324, a late-stage investigational bispecific antibody, to its ophthalmology pipeline. OLN324 is being developed for retinal vascular diseases, specifically wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The transaction also includes potential regulatory and commercial milestone payments of up to approximately $1.125 billion. Separately, Blackstone Life Sciences will provide $750 million to fund the candidate’s Phase 3 development, contingent upon completion of the acquisition.

Acquisition Adds Late-Stage Retinal Disease Candidate

The proposed acquisition will expand J&J’s ophthalmology portfolio with OLN324, a next-generation bispecific antibody designed to target vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), two biological pathways involved in retinal vascular diseases.

Designed in a compact protein format known as a minibody, OLN324 combines a small molecular size with high Ang2 potency. According to J&J, this design could enable improved control of retinal fluid and potentially support more sustained disease management.

The candidate is being developed for wet AMD and DME, conditions that collectively affect more than 40 million people worldwide and are major causes of vision loss. Its addition would strengthen J&J’s pipeline in retinal therapeutics by bringing a Phase 3-stage investigational candidate targeting both conditions.

Dual-Targeting Approach Could Differentiate OLN324

OLN324 is designed to simultaneously inhibit VEGF and Ang2 pathways, which contribute to abnormal blood vessel activity and retinal disease progression. By targeting both pathways, the candidate aims to achieve improved disease control, including greater reduction in retinal fluid and potentially longer intervals between treatments.

The combination of high Ang2 potency and a minibody format represents the central differentiation of OLN324 within the proposed acquisition. According to J&J, these characteristics could support more sustained disease management in patients requiring ongoing treatment for retinal vascular diseases.

However, OLN324 remains investigational, and its potential advantages in retinal fluid control, treatment durability and clinical outcomes will need to be established through further clinical evaluation, particularly as it advances through Phase 3 development.

Blackstone to Fund Phase 3 Development

Alongside the proposed acquisition, J&J will enter into a separate multi-year development funding agreement with Blackstone Life Sciences to support OLN324’s Phase 3 clinical programme.

Under the agreement, Blackstone will provide a total of $750 million to J&J over multiple years to fully fund Phase 3 development. In return, Blackstone will be eligible to receive certain regulatory and sales milestone payments, as well as single-digit royalties.

The arrangement establishes a dedicated funding mechanism for the candidate’s late-stage development, with Blackstone’s returns linked to regulatory and commercial milestones. The funding agreement is contingent upon completion of the Ollin acquisition.

Transaction and Financial Details

J&J will pay $2.2 billion upfront to acquire Ollin Biosciences, with the possibility of additional regulatory and commercial milestone payments of up to approximately $1.125 billion. This brings the potential total acquisition consideration to approximately $3.325 billion, excluding the separate $750 million Blackstone development funding arrangement.

The transaction is expected to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions. J&J has stated that the accounting treatment of the Blackstone funding arrangement will be communicated on or before the transaction closes.

 Strategic Outlook

The acquisition supports J&J’s ambition to strengthen its ophthalmology portfolio by adding a late-stage investigational candidate targeting two major biological pathways involved in retinal vascular diseases.

For J&J, OLN324 represents an opportunity to expand its pipeline in wet AMD and DME, where sustained disease control and treatment durability remain important clinical considerations. The candidate’s dual-targeting mechanism and minibody design provide the proposed basis for differentiation.

Advancing OLN324 through Phase 3 studies will be critical to determining whether these characteristics translate into improved retinal fluid control, meaningful clinical benefits and potentially longer treatment intervals for patients.

 Reference

Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology, Johnson & Johnson, 16 November 2026

About the Writer

Mayuri Vaja (Linkedin) is a Pharm.D professional with a strong interest in clinical research, pharmacovigilance, and medical writing, supported by certifications in pharmacovigilance and academic projects exploring AI in healthcare and drug safety.
With a growing focus on evidence-based healthcare and scientific communication, she is developing expertise in clinical research and translating healthcare evidence into clear, meaningful content.
As a Pharmacally healthcare writer, Mayuri is committed to creating accurate, research-driven, and clinically relevant healthcare content while continuously strengthening her professional skills.


Share on Social Media
Scroll to Top